 |
|
A Pedigree With a Novel Presenilin 1 Mutation at a Residue That Is Not Conserved in Presenilin 2
Minoru Yasuda, MD;
Kiyoshi Maeda, MD;
Mamoru Hashimoto, MD;
Hikari Yamashita, MA;
Yoshitaka Ikejiri, MD;
Thomas D. Bird, MD;
Chikako Tanaka, PhD;
Gerard D. Schellenberg, PhD
Arch Neurol. 1999;56:65-69.
Objective To disclose a novel mutation of the presenilin 1 (PS1) gene responsible for early-onset Alzheimer disease and to clarify genotype-phenotype correlation that should help to establish the function of this protein.
Background The PS1 and presenilin 2 (PS2) genes carry missense mutations in families with Alzheimer disease. The PS1 and PS2 proteins have similar structures, and all presently known mutations are in nucleotides coding for amino acids that are conserved between the 2 presenilins.
Methods Sequence and restriction fragment length polymorphism analyses of PS1 gene of DNA from a pedigree with early-onset Alzheimer disease.
Results Sequence analysis disclosed a novel PS1 mutation in a pedigree of Japanese origin with early-onset Alzheimer disease. This mutation, which is predicted to cause a missense substitution of lysine for glutamic acid, occurred at codon 123 of PS1 that was not a conserved residue in PS2. The 2 patients of this pedigree shared an early clinical phenotype consisting of later-onset, progressive aphasia, but preserved visuospatial ability, which was indistinguishable from those of other PS1-associated Alzheimer disease cases.
Conclusion These results demonstrate that a missense mutation in a region not conserved between PS1 and PS2 can cause Alzheimer disease.
From the Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan (Drs Yasuda, Maeda, Hashimoto, Ikejiri, Bird, and Tanaka and Mr Yamashita); Geriatric Research Education Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Wash (Drs Yasuda and Schellenberg); Department of Psychiatry, Osaka University Medical School, Osaka, Japan (Dr Ikejiri); and Department of Neurology (Drs Bird and Schellenberg) and Division of Gerontology and Geriatric Medicine, Department of Pharmacology (Dr Schellenberg), University of Washington, Seattle.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(1):129-131.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer's disease
Heckmann et al.
Brain 2004;127:133-142.
ABSTRACT
| FULL TEXT
Screening for PS1 mutations in a referral-based series of AD cases: 21 Novel mutations
Rogaeva et al.
Neurology 2001;57:621-625.
ABSTRACT
| FULL TEXT
A Novel Presenilin 1 Mutation (Leu166Arg) Associated With Early-Onset Alzheimer Disease
Ezquerra et al.
Arch Neurol 2000;57:485-488.
ABSTRACT
| FULL TEXT
|
